303 related articles for article (PubMed ID: 23543091)
21. Effect of naltrexone on human alcohol consumption.
Swift RM
J Clin Psychiatry; 1995; 56 Suppl 7():24-9. PubMed ID: 7673102
[TBL] [Abstract][Full Text] [Related]
22. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking.
Krishnan-Sarin S; Krystal JH; Shi J; Pittman B; O'Malley SS
Biol Psychiatry; 2007 Sep; 62(6):694-7. PubMed ID: 17336941
[TBL] [Abstract][Full Text] [Related]
23. Alcohol addiction and the mu-opioid receptor.
Berrettini W
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Feb; 65():228-33. PubMed ID: 26226591
[TBL] [Abstract][Full Text] [Related]
24. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.
Oslin DW; Berrettini W; Kranzler HR; Pettinati H; Gelernter J; Volpicelli JR; O'Brien CP
Neuropsychopharmacology; 2003 Aug; 28(8):1546-52. PubMed ID: 12813472
[TBL] [Abstract][Full Text] [Related]
25. A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.
Vallender EJ; Rüedi-Bettschen D; Miller GM; Platt DM
Drug Alcohol Depend; 2010 Jun; 109(1-3):252-6. PubMed ID: 20153935
[TBL] [Abstract][Full Text] [Related]
26. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Kranzler HR; Armeli S; Covault J; Tennen H
Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
[TBL] [Abstract][Full Text] [Related]
27. Stress-induced and cue-induced craving for alcohol in heavy drinkers: Preliminary evidence of genetic moderation by the OPRM1 and CRH-BP genes.
Ray LA
Alcohol Clin Exp Res; 2011 Jan; 35(1):166-74. PubMed ID: 21039637
[TBL] [Abstract][Full Text] [Related]
28. Opioid pharmacogenetics of alcohol addiction.
Berrettini W
Cold Spring Harb Perspect Med; 2013 Jul; 3(7):. PubMed ID: 23729643
[TBL] [Abstract][Full Text] [Related]
29. Genes harbor clues to addiction, recovery.
Hampton T
JAMA; 2004 Jul; 292(3):321-2. PubMed ID: 15265836
[No Abstract] [Full Text] [Related]
30. Pharmacologic approaches to the management of alcoholism.
Anton RF
J Clin Psychiatry; 2001; 62 Suppl 20():11-7. PubMed ID: 11584870
[TBL] [Abstract][Full Text] [Related]
31. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
[TBL] [Abstract][Full Text] [Related]
32. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.
Oroszi G; Anton RF; O'Malley S; Swift R; Pettinati H; Couper D; Yuan Q; Goldman D
Alcohol Clin Exp Res; 2009 Mar; 33(3):383-93. PubMed ID: 19053977
[TBL] [Abstract][Full Text] [Related]
33. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden.
Bart G; Kreek MJ; Ott J; LaForge KS; Proudnikov D; Pollak L; Heilig M
Neuropsychopharmacology; 2005 Feb; 30(2):417-22. PubMed ID: 15525999
[TBL] [Abstract][Full Text] [Related]
34. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
Kim SG; Kim CM; Choi SW; Jae YM; Lee HG; Son BK; Kim JG; Choi YS; Kim HO; Kim SY; Oslin DW
Psychopharmacology (Berl); 2009 Jan; 201(4):611-8. PubMed ID: 18795264
[TBL] [Abstract][Full Text] [Related]
35. Study suggests gene may predict success of therapies for alcohol dependence.
Kuehn BM
JAMA; 2011 Mar; 305(10):984-5. PubMed ID: 21386072
[No Abstract] [Full Text] [Related]
36. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
[TBL] [Abstract][Full Text] [Related]
37. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
Lin Y; Kranzler HR; Farrer LA; Xu H; Henderson DC; Zhang H
Pharmacogenomics J; 2020 Oct; 20(5):672-680. PubMed ID: 32029903
[TBL] [Abstract][Full Text] [Related]
38. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
Goldman D; Oroszi G; O'Malley S; Anton R
J Stud Alcohol Suppl; 2005 Jul; (15):56-64; discussion 33. PubMed ID: 16223057
[TBL] [Abstract][Full Text] [Related]
39. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
40. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects.
Weerts EM; Kim YK; Wand GS; Dannals RF; Lee JS; Frost JJ; McCaul ME
Neuropsychopharmacology; 2008 Feb; 33(3):653-65. PubMed ID: 17487229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
